Skip to Content

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

Late-breaking data from EHA 2022 present phase 2 results from the first multi-center randomized trial comparing two chemotherapy regimens in Burkitt lymphoma (BL). 

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top